ALS (motor neurone disease) trials in Germany

In Germany 18 Also abroad 225

18 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
Where
Luebeck, Rostock, Ulm
Age
18 years to 75 years
People
36 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07100119 · EU 2025-521295-60-00
No phaseTaking people
Register for Medical Data, Functional Scales, and Care Outcomes in ALS, SMA, and Other Motor System Disorders
Where
Berlin
People
2,000
Run by
Ambulanzpartner Soziotechnologie APST GmbH
See details and how to joinNCT07900672
Phase 3Taking people
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
Where
Berlin, Bonn, Hanover, Jena, Lübeck, Ulm
Age
18 years to 80 years
People
500 worldwide
Run by
Prilenia
See details and how to joinNCT07322003
Phase 2Taking people
Evaluation of the efficacy and safety of Rituximab in patients with Amyotrophic Lateral Sclerosis (ALS)
Where
Berlin, Bonn, Munich
Age
18 years and over
People
52
Run by
Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.
See details and how to join2022-502743-35-00 · EU 2022-502743-35-00
Phase 1/2Taking people
FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS
Where
Lübeck, Munich, Rostock
Age
18 years to 75 years
People
30 worldwide
Run by
Trace Neuroscience, Inc.
See details and how to joinNCT07674667
Phase 1/2Taking people
A Randomized Phase 1 / 2 Trial Aiming to Restore UNC13A Function in People living with ALS: FUNCtion ALS
Where
Luebeck, Munich, Rostock, Ulm
Age
18 years and over
People
20 worldwide
Run by
Trace Neuroscience Inc.
See details and how to join2025-523111-11-00 · EU 2025-523111-11-00
Phase 1Taking people
A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
Where
Lübeck, Rostock, Ulm
Age
18 years to 80 years
People
32 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07571174
Phase 1Taking people
A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS)
Where
Luebeck, Rostock, Ulm
Age
18 years to 80 years
People
32 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07571200 · EU 2026-525574-19-00
Phase 1/2Taking people
First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)
Where
Ulm
Age
18 years and over
People
54 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06351592 · EU 2023-510344-20-00
Phase 2Taking people
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
Where
Dresden, Hanover, Jena, Luebeck, Rostock, Ulm
Age
18 years and over
People
240 worldwide
Run by
Zydus Therapeutics Inc.
See details and how to joinNCT07023835 · EU 2025-522580-15-00
Phase 1/2Taking people
A Study of LTX-002 in Adult Participants With Amyotrophic Lateral Sclerosis
Where
Berlin, Luebeck
Age
18 years to 75 years
People
56 worldwide
Run by
Leal Therapeutics, Inc
See details and how to joinNCT07660614 · EU 2025-522039-33-00
No phaseTaking people
French-German Cohort Study to Determine Factors Associated With Weight Loss in Amyotrophic Lateral Sclerosis
Where
Hanover, Ulm
Age
18 years and over
People
1,000 worldwide
Run by
University Hospital, Limoges
See details and how to joinNCT06147843
Phase 2Taking people
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
Where
Berlin, Hanover, Lübeck
Age
18 years to 75 years
People
105 worldwide
Run by
PhenoNet, Inc.
See details and how to joinNCT07142291
Phase 3Taking people
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS (PREVAiLS)
Where
Berlin, Bonn, Hanover, Jena, Luebeck, Ulm
Age
18 years and over
People
420 worldwide
Run by
Ferrer Internacional S.A.
See details and how to join2025-524002-16-00 · EU 2025-524002-16-00
No phaseTaking people
Hypercaloric PEG Nutrition in ALS to Sustain Energy Homeostasis
Where
Ulm
Age
18 years and over
People
76
Run by
University of Ulm
See details and how to joinNCT06877143
Phase 3Not yet taking people in Germany
Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients
Where
Bonn, Göttingen, Jena, Leipzig, München
Age
18 years to 80 years
People
412 worldwide
Run by
AB Science
See details and how to joinNCT07174492 · EU 2024-511244-12-01
Phase 3Taking people
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
Where
Ulm
Age
18 years to 81 years
People
495 worldwide
Run by
AB Science
See details and how to joinNCT03127267
No phaseEnrolling by invitation
Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disorders
Where
München
Age
18 years to 65 years
People
108
Run by
LMU Klinikum
See details and how to joinNCT06605612